Macrotroponin in the COVID-19 Era: An Under-Recognised Cause of Persistent Troponin Elevation

Hannah Kempton; Graham Jones; Michael McCready; Jason Kovacic

doi:10.1016/j.hlc.2024.03.007

Macrotroponin in the COVID-19 Era: An Under-Recognised Cause of Persistent Troponin Elevation

Heart Lung Circ. 2024 May 4:S1443-9506(24)00168-9. doi: 10.1016/j.hlc.2024.03.007. Online ahead of print.

Authors

Hannah Kempton¹, Graham Jones², Michael McCready³, Jason Kovacic⁴

Affiliations

¹ Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia; The University of New South Wales, Sydney, NSW, Australia. Electronic address: hannah.kempton2@svha.org.au.
² Department of Pathology, St Vincent's Hospital, Sydney, NSW, Australia.
³ Department of Cardiology, Wagga Wagga Base Hospital, Wagga Wagga, NSW, Australia.
⁴ Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia; The University of New South Wales, Sydney, NSW, Australia; The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.

PMID: 38705780
DOI: 10.1016/j.hlc.2024.03.007

Abstract

Troponin is an important diagnostic tool, however, as the assay sensitivity and frequency of testing has increased in the COVID-19 era, a new cohort of patients with persistently elevated troponin has emerged. Interfering antibodies should be considered in patients with persistent and stable troponin elevation, where there is no ongoing cause.

Keywords: Macrotroponin; Myocardial infarction; Troponin.